|
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 9,362.00 JPY | -0.71% |
|
-2.34% | +13.58% |
| 02-24 | Sarepta Therapeutics, Inc. Announces Commercial Launch of ELEVIDYS in Japan | CI |
| 02-24 | Sarepta Therapeutics Says Elevidys Available in Japan for Duchenne Muscular Dystrophy | MT |
| Capitalization | 15,407B 96.53B 84.38B 76.23B 72.93B 133B 8,929B 138B 911B 361B 4,266B 362B 355B | P/E ratio 2025 |
31.3x | P/E ratio 2026 * | 31.2x |
|---|---|---|---|---|---|
| Enterprise value | 14,511B 90.92B 79.47B 71.8B 68.68B 125B 8,409B 130B 858B 340B 4,018B 341B 334B | EV / Sales 2025 |
10.4x | EV / Sales 2026 * | 10.4x |
| Free-Float |
38.09% | Yield 2025 |
3.3% | Yield 2026 * | 1.46% |
Last Transcript: Chugai Pharmaceutical Co., Ltd.
| 1 day | -0.71% | ||
| 1 week | -2.34% | ||
| Current month | -10.45% | ||
| 1 month | +0.88% | ||
| 3 months | +9.59% | ||
| 6 months | +39.75% | ||
| Current year | +13.58% |
| 1 week | 9,116 |  | 9,702 |
| 1 month | 9,116 | | 10,700 |
| Current year | 8,168 | | 10,700 |
| 1 year | 5,942 | | 10,700 |
| 3 years | 3,203 | | 10,700 |
| 5 years | 3,191 | | 10,700 |
| 10 years | 1,003.33 | | 10,700 |
| Manager | Title | Age | Since |
|---|---|---|---|
Osamu Okuda
CEO | Chief Executive Officer | 62 | 31/12/2020 |
Iwaaki Taniguchi
DFI | Director of Finance/CFO | - | 27/03/2024 |
Junichi Nezu
CTO | Chief Tech/Sci/R&D Officer | - | - |
| Director | Title | Age | Since |
|---|---|---|---|
Motoo Ueno
BRD | Director/Board Member | 68 | 28/02/1993 |
Masayuki Oku
BRD | Director/Board Member | 81 | 28/02/2015 |
| Director/Board Member | 77 | 28/02/2017 |
| Name | Varia. Jan 1. | Weight | AuM | |
|---|---|---|---|---|
 | +8.20% | 6.57% | 29 M€ | |
| +4.01% | 1.87% | 69 M€ | |
| +2.14% | 1.59% | 4 M€ | |
| +6.75% | 1.53% | 73,790 M€ |
| Change | 5d. change | 1-year change | 3-years change | Capi.($) | ||
|---|---|---|---|---|---|---|
| -0.71% | -2.34% | +36.13% | +181.31% | 96.53B | |
| +0.80% | -0.53% | +22.88% | +203.58% | 880B | |
| -0.21% | +0.47% | +48.18% | +57.79% | 582B | |
| -2.52% | -4.53% | +3.84% | +44.57% | 388B | |
| +0.79% | -6.01% | +5.81% | +21.36% | 324B | |
| +0.11% | -0.83% | +21.02% | +34.57% | 295B | |
| +0.43% | -1.54% | +25.20% | +62.42% | 293B | |
| -0.26% | -0.16% | +22.07% | +9.34% | 286B | |
| -0.43% | -0.90% | +17.13% | +57.05% | 197B | |
| +0.42% | +0.74% | +27.91% | +82.35% | 180B | |
| Average | -0.33% | -1.56% | +23.02% | +75.44% | 352.27B | |
| Weighted average by Cap. | -0.39% | -1.40% | +23.66% | +88.51% |
| 2025 | 2026 * | |
|---|---|---|
| Net sales | 1,247B 7.81B 6.83B 6.17B 5.9B 10.73B 723B 11.16B 73.7B 29.21B 345B 29.32B 28.7B | 1,376B 8.62B 7.54B 6.81B 6.51B 11.85B 798B 12.32B 81.34B 32.24B 381B 32.36B 31.67B |
| Net income | 428B 2.68B 2.34B 2.12B 2.03B 3.69B 248B 3.83B 25.3B 10.03B 119B 10.07B 9.85B | 494B 3.1B 2.71B 2.44B 2.34B 4.25B 286B 4.42B 29.2B 11.57B 137B 11.62B 11.37B |
| Net Debt | -896B -5.62B -4.91B -4.43B -4.24B -7.72B -519B -8.02B -52.97B -20.99B -248B -21.07B -20.63B | -1,077B -6.75B -5.9B -5.33B -5.1B -9.28B -624B -9.64B -63.69B -25.24B -298B -25.33B -24.8B |
| Date | Price | Change | Volume |
|---|---|---|---|
| 13/03/26 | 9,362.00 ¥ | -0.71% | 2,111,400 |
| 12/03/26 | 9,429.00 ¥ | -0.38% | 1,817,300 |
| 11/03/26 | 9,465.00 ¥ | -0.58% | 1,565,100 |
| 10/03/26 | 9,520.00 ¥ | +0.42% | 2,228,900 |
| 09/03/26 | 9,480.00 ¥ | -1.11% | 3,117,600 |
Trader
This super rating is the result of a weighted average of the rankings based on the following ratings: Global Valuation (Composite), EPS Revisions (4 months), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Investor
This super composite rating is the result of a weighted average of the rankings based on the following ratings: Fundamentals (Composite), Global Valuation (Composite), EPS Revisions (1 year), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Global
This composite rating is the result of an average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), Financial Estimates Revisions (Composite), Consensus (Composite), and Visibility (Composite). The company must be covered by at least 4 of these 5 ratings for the calculation to be performed. We recommend that you carefully review the associated descriptions.
Quality
This composite rating is the result of an average of the rankings based on the following ratings: Capital Efficiency (Composite), Quality of Financial Reporting (Composite), and Financial Health (Composite). The company must be covered by at least 2 of these 3 ratings for the calculation to be performed. We recommend that you carefully review the associated descriptions.
ESG MSCI
The MSCI ESG score assesses a company’s environmental, social, and governance practices relative to its industry peers. Companies are rated from CCC (laggard) to AAA (leader). This rating helps investors incorporate sustainability risks and opportunities into their investment decisions.
Quarterly revenue - Rate of surprise
- Stock Market
- Equities
- 4519 Stock
Select your edition
All financial news and data tailored to specific country editions
MarketScreener is also available in this country: United States.
Switch edition